You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Drake CG, Quinn D, Dreicer R, et al
Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
Journal for ImmunoTherapy of Cancer 2015;3:P145. doi: 10.1186/2051-1426-3-S2-P145